Almac validate Illumina TruSight® Tumor 170 Assay - Almac

<img alt="" src="https://secure.easy7bear.com/213487.png" style="display:none;" />

Home / Knowledge Centre /

Diagnostic Services / Almac validate Illumina TruSight® Tumor 170 Assay

Webinar

Almac validate Illumina TruSight® Tumor 170 Assay

In this webinar, Dr Leeona Galligan, VP UK Operations at Almac Diagnostic Services will discuss:

An overview on Almac Diagnostic Services
TruSight® Tumor 170 overview
TruSight® Tumor 170 Analytical Validation at Almac
Clinical Trial Framework for TruSight® Tumor 170 at Almac

For more information visit our Current Assay section.

Related Resources

DNA Damage Response Deficiency Assay predicts response to treatment in ovarian cancer

DNA Damage Response Deficiency Assay predicts response to treatment in ovarian cancer

Stay up-to-date with the latest from Almac

Join our mailing list

This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies